Drug Trial Radar · NCT06055985
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
207
Actual
Start
Nov 17, 2023
Primary completion
Mar 31, 2025
Study completion Apr 11, 2025
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Conditions
- Parkinson Disease
Interventions
PlaceboOther
Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
UCB0022Drug
Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Visit 9 (Day 70) in the average number of hours/day of OFF time, as assessed by the study participant-completed Hauser PD symptoms diary over 3 consecutive daysTime frame: From Baseline (Day 1) to Visit 9 (Day 70)
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
Pd0060 50506
Phoenix, Arizona
Pd0060 50590
Scottsdale, Arizona
Pd0060 50608
Little Rock, Arkansas
Pd0060 50519
Fountain Valley, California
Pd0060 50428
Fresno, California
Pd0060 50601
Loma Linda, California
Pd0060 50589
Los Alamitos, California
Pd0060 50587
Los Angeles, California
Pd0060 50452
Pasadena, California
Pd0060 50598
Englewood, Colorado
Pd0060 50628
New Haven, Connecticut
Pd0060 50610
Newark, Delaware
Pd0060 50600
Altamonte Springs, Florida
Pd0060 50616
Aventura, Florida
Pd0060 50596
Boca Raton, Florida
Pd0060 50524
Bradenton, Florida
Pd0060 50647
DeLand, Florida
Pd0060 50577
Doral, Florida
Pd0060 50584
Hollywood, Florida
Pd0060 50582
Miami, Florida
Pd0060 50579
Miami, Florida
Pd0060 50449
Miami, Florida
Pd0060 50580
Miami, Florida
Pd0060 50597
Naples, Florida
Pd0060 50591
Ocala, Florida
Pd0060 50605
Port Orange, Florida
Pd0060 50620
St. Petersburg, Florida
Pd0060 50603
Tampa, Florida
Pd0060 50585
Winter Park, Florida
Pd0060 50075
Augusta, Georgia
Pd0060 50595
Indianapolis, Indiana
Pd0060 50319
Iowa City, Iowa
Pd0060 50074
Kansas City, Kansas
Pd0060 50561
Lexington, Kentucky
Pd0060 50615
Boston, Massachusetts
Pd0060 50085
Boston, Massachusetts
Pd0060 50627
North Dartmouth, Massachusetts
Pd0060 50110
Ann Arbor, Michigan
Pd0060 50545
East Lansing, Michigan
Pd0060 50386
Farmington Hills, Michigan
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.